Purpose of this Study
At various visits, you will have blood tests, eye exams, and vision tests.
Who Can Participate?
Eligibility
Copilot said: Here is a summary for a 5th grade audience, without contractions, apostrophes, or bullet points:
People can join this study if they are older adults. Some parts of the study include people age 65 and older, and other parts include people age 55 and older. They must have a vision problem called geographic atrophy caused by age related macular degeneration. They cannot have had previous treatments for this condition in the study eye, except for vitamin supplements. They also cannot have had any gene therapy or cell therapy treatments before.
Age Range
55-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is testing a new medicine called CTx001 for people who have a vision problem called geographic atrophy, which is caused by age related macular degeneration. Researchers want to find the best dose of this medicine and learn if it is safe and works well. The goal is to see if CTx001 can help slow down or improve this eye condition.
Locations
Duke University Hospital
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
A First in Human Phase 1/2 Multi-center Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CTx001 Administered via a Single Subretinal Injection in Participants with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) - (Opti-Gain)
Principal Investigator
Lejla
Vajzovic
Protocol Number
PRO00120577
Phase
I/II
Enrollment Status
Pending Open to Enrollment